Kezar Life Sciences Inc (KZR) USD0.001
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company is developing small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single. The Company's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor being evaluated in Phase II clinical trials in lupus nephritis, dermatomyositis, and polymyositis. In addition, KZR-261 is an anti-cancer clinical candidate targeting the Sec61 translocon and the protein secretion pathway. The Company is focusing its initial development of KZR-616 in severe, chronic and orphan immune-mediated diseases. The Company’s principal operations are in South San Francisco, California.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.